Synonyms
- B1502
- Carbamazepine Sensitivity
- HLA B*1502
- HLA B1502
Special Instructions
If you have questions, please call 800-533-1037 (HLA customer service) for assistance in selecting the proper HLA test for the patient.
Expected Turnaround Time
3 - 7 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Related Documents
Specimen Requirements
Specimen
Whole blood or buccal swabs
Minimum Volume
7 mL whole blood or four buccal swabs
Container
Lavender-top (EDTA) tube or four buccal swabs in a sealed envelope (buccal swab kit). When submitting buccal swabs, please use a buccal swab kit provided by LabCorp. To obtain the buccal kit, please telephone 800-533-1037.
Storage Instructions
Maintain whole blood at room temperature or refrigerate. Keep buccal swabs dry and at room temperature.
Causes for Rejection
Hemolysis; clotted specimen; insufficient volume of DNA
Test Details
Use
This test has been recommended for patients of Asian descent who are being considered for carbamazepine therapy. The utility of this test for patients of other ethnic backgrounds has not been established.
Limitations
Even with appropriate precautions, an occasional specimen may not be satisfactory for testing. In such cases, an additional specimen should be collected for retesting.
This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA).
Methodology
Sequence-based typing (SBT), sequence-specific oligonucleotide probes (SSOP), and/or sequence-specific primers (SSP) as needed to obtain the required resolution.
References
Alfirevic A, Jorgensen AL, Williamson PR, Chadwick DW, Park BK, Pirmohamed M.. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics J. 2006 Sep; 7(6):813-818.
Chung WH, Hung SI, Hong HS, et al. Medical genetics: A marker for Stevens-Johnson syndrome. Nature. 2004 Apr 1; 428(6982):486.
Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics. 2006 Apr; 16(4):297-306.
Lonjou C, Thomas L, Borot N, et al. A marker for Stevens-Johnson syndrome: Ethnicity matters. Pharmacogenomics J. 2006 Jul-Aug; 6(4):265-268.
LOINC® Map
| Order Code | Order Code Name | Order Loinc | Result Code | Result Code Name | UofM | Result LOINC |
|---|---|---|---|---|---|---|
| 167129 | HLA-B*15:02 | 019422 | HLA-B | 57979-7 | ||
| 167129 | HLA-B*15:02 | 019423 | HLA-B | 57979-7 | ||
| 167129 | HLA-B*15:02 | 167384 | HLA Methodology | 49549-9 |
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf